Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma
Pierre I Karakiewicz,1 Louise Nott,2 Abhishek Joshi,3 George Kannourakis,4,5 Jamal Tarazi,6 Mahmood Alam7 1Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada; 2Department of Haematology and Oncology, Royal Hobart Hospital, Hobart, TAS, 3Townsvill...
Main Authors: | Karakiewicz PI, Nott L, Joshi A, Kannourakis G, Tarazi J, Alam M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-05-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/evaluation-of-response-from-axitinib-per-response-evaluation-criteria--peer-reviewed-article-OTT |
Similar Items
-
Design, Synthesis, and Biological Evaluation of Axitinib Derivatives
by: Na Wei, et al.
Published: (2018-03-01) -
Axitinib in metastatic renal cell carcinoma: single center experience
by: Agnieszka Buraczewska, et al.
Published: (2017-01-01) -
Axitinib in sequential therapy in metastatic renal cell carcinoma
by: Agata Kuchar, et al.
Published: (2015-05-01) -
Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)
by: Ibon Gurruchaga Sotés, et al.
Published: (2021-06-01) -
Is that Beauty? Cody Choi
by: Rosa Fernández Gómez
Published: (2017-01-01)